NB Health Laboratory

Executive Summary

NB Health Laboratory (NBHL) is a Japanese biotechnology company pioneering functional monoclonal antibodies targeting G-protein coupled receptors (GPCRs) through its proprietary MoGRAA® Discovery Engine. The platform enables the generation of high-specificity antibodies against GPCRs, a challenging but therapeutically valuable class of targets. NBHL's initial focus is on fibrosis, where GPCR modulation holds promise for reversing or halting disease progression. Based in Sapporo, the company operates at the preclinical stage with a lean team of 10–50 employees. While still early-stage, NBHL's technology could unlock new treatment paradigms for fibrotic diseases and other GPCR-driven conditions, positioning it as a potential partner or acquisition target for larger pharmaceutical companies seeking novel biologics. The company's progress will depend on successful validation of its platform through preclinical studies and securing additional funding to advance its pipeline.

Upcoming Catalysts (preview)

• Q2 2027Preclinical proof-of-concept data for lead anti-GPCR antibody in fibrosis models40% success
• Q4 2026Partnership or licensing deal with a major pharmaceutical company for MoGRAA platform30% success
• Q3 2026Series A or B financing round to support IND-enabling studies45% success